Catheter management across patients with hematologic malignancies and catheter-related blood stream infections: a systematic review

Ann Hematol. 2022 Nov;101(11):2515-2524. doi: 10.1007/s00277-022-04969-7. Epub 2022 Sep 15.

Abstract

Catheter-related bloodstream infection (CRBSI) can lead to ICU admission in patients with hematologic malignancy (HM). Variability exists in the management of catheters given the need for long-term access and co-existing thrombocytopenia or coagulopathy. We conducted a systematic review to evaluate catheter management in patients with CRBSI. Literature searches were conducted up to December 20, 2021 across MEDLINE, EMBASE, CENTRAL, CINAHL, and PubMed. Observational studies and RCTs of adults (> 16) with HM were included. Our primary outcome was mortality and secondary outcomes included infection recurrence and ICU admission. We identified 23 studies (N = 2026 patients), of which 22 were observational. Across the 12 studies (N = 801) that reported on bacterial organisms, 528 (65.9%) were gram positive, and 273 (34.1%) were gram negative. Catheters were removed in 1266 (62%) and retained in 760 (38%) patients. Removal was associated with a mean 30-day mortality of 13.14% (SD 9.12; 90/685) and reinfection rate of 5.49% (SD 2.88; 22/401) compared to 39.23% (SD 14.58; 122/311) and 10.75% (SD 21.07; 10/93), respectively, if retained. Catheter retention may be associated with a higher risk of mortality and infection recurrence. Further prospective research should assess catheter management in this population, including potential harms associated with retention.

Keywords: CRBSI; Catheter management; Critical care; Hematologic malignancies; Systematic review.

Publication types

  • Systematic Review

MeSH terms

  • Adult
  • Bacteremia* / complications
  • Catheter-Related Infections* / epidemiology
  • Catheter-Related Infections* / etiology
  • Catheterization, Central Venous* / adverse effects
  • Catheters
  • Central Venous Catheters*
  • Hematologic Neoplasms* / complications
  • Hematologic Neoplasms* / therapy
  • Humans